DK3246399T3 - Alfavirus-partikler og fremgangsmåder til fremstilling - Google Patents

Alfavirus-partikler og fremgangsmåder til fremstilling Download PDF

Info

Publication number
DK3246399T3
DK3246399T3 DK17163152.6T DK17163152T DK3246399T3 DK 3246399 T3 DK3246399 T3 DK 3246399T3 DK 17163152 T DK17163152 T DK 17163152T DK 3246399 T3 DK3246399 T3 DK 3246399T3
Authority
DK
Denmark
Prior art keywords
alfavirus
particles
manufacturing methods
manufacturing
methods
Prior art date
Application number
DK17163152.6T
Other languages
English (en)
Inventor
Jonathan F Smith
Sergey Dryga
Harold Alterson
Jon Rayner
Kim Alterson
Maureen F Maughan
Kurt Kamrud
Original Assignee
Alphavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alphavax Inc filed Critical Alphavax Inc
Application granted granted Critical
Publication of DK3246399T3 publication Critical patent/DK3246399T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation
    • C12N2770/36162—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicinal Preparation (AREA)
DK17163152.6T 2002-12-13 2003-12-12 Alfavirus-partikler og fremgangsmåder til fremstilling DK3246399T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43305802P 2002-12-13 2002-12-13
EP10011537.7A EP2290054B1 (en) 2002-12-13 2003-12-12 Alphavirus particles and methods for preparation

Publications (1)

Publication Number Publication Date
DK3246399T3 true DK3246399T3 (da) 2021-10-04

Family

ID=32595112

Family Applications (3)

Application Number Title Priority Date Filing Date
DK17163152.6T DK3246399T3 (da) 2002-12-13 2003-12-12 Alfavirus-partikler og fremgangsmåder til fremstilling
DK03813433.4T DK1590451T3 (da) 2002-12-13 2003-12-12 Alfaviruspartikler og fremgangsmåder til fremstilling
DK10011537.7T DK2290054T3 (da) 2002-12-13 2003-12-12 Alfavirus-partikler og fremgangsmåder til fremstilling deraf

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK03813433.4T DK1590451T3 (da) 2002-12-13 2003-12-12 Alfaviruspartikler og fremgangsmåder til fremstilling
DK10011537.7T DK2290054T3 (da) 2002-12-13 2003-12-12 Alfavirus-partikler og fremgangsmåder til fremstilling deraf

Country Status (13)

Country Link
US (1) US7078218B2 (da)
EP (3) EP2290054B1 (da)
JP (2) JP5079981B2 (da)
AU (1) AU2003297041B2 (da)
BR (2) BR122019005271B1 (da)
CA (2) CA2807515C (da)
DK (3) DK3246399T3 (da)
ES (3) ES2552687T3 (da)
HK (1) HK1082524A1 (da)
IL (1) IL169076A (da)
NZ (1) NZ540657A (da)
WO (1) WO2004055167A2 (da)
ZA (1) ZA200505517B (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
US7045335B2 (en) * 2001-09-06 2006-05-16 Alphavax, Inc. Alphavirus replicon vector systems
WO2004055167A2 (en) 2002-12-13 2004-07-01 Alphavax, Inc. Alphavirus particles and methods for preparation
JP4991108B2 (ja) * 2002-12-13 2012-08-01 アルファバックス，インコーポレイティド 多抗原性アルファウイルス・レプリコン粒子及び方法
EP1608762B1 (en) * 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
AU2004257214B2 (en) * 2003-07-11 2010-04-22 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines
CA2567254C (en) * 2004-05-18 2012-03-13 Alphavax, Inc. Tc-83-derived alphavirus vectors, particles and methods
EP1773403B1 (en) * 2004-07-09 2018-04-25 The University of North Carolina At Chapel Hill Alphavirus-based adjuvants
US20080292658A1 (en) * 2004-11-11 2008-11-27 Emmie De Wit Defective Influenza Virus Particles
US8486420B2 (en) * 2005-02-15 2013-07-16 The University Of North Carolina At Chapel Hill Live virus vaccines
EP1907537A4 (en) * 2005-07-14 2010-11-10 Mayo Foundation PREPARATIONS BASED ON PARAMYXOVIRIDAE VIRUS
US20100233209A1 (en) * 2005-08-11 2010-09-16 Higgs Stephen T Chikungunya virus infectious clones and uses therefor
US8202535B2 (en) * 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) * 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US20070299687A1 (en) * 2006-06-23 2007-12-27 Pamela Palmer Inpatient system for patient-controlled delivery of oral transmucosal medications dosed as needed
NZ575476A (en) 2006-09-12 2012-07-27 Alphavax Inc Alphavirus replicon particles encoding il- 12 as immunological adjuvants
WO2008033966A2 (en) * 2006-09-12 2008-03-20 Alphavax, Inc. Alphavirus replicon particles matched to protein antigens as immunological adjuvants
EP2099485B1 (en) * 2006-11-03 2018-03-21 AlphaVax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
US20080294361A1 (en) * 2007-05-24 2008-11-27 Popp Shane M Intelligent execution system for the monitoring and execution of vaccine manufacturing
CA2689588C (en) 2007-06-21 2016-08-23 Alphavax, Inc. Promoterless cassettes for expression of alphavirus structural proteins
EP2205751A2 (en) * 2007-09-26 2010-07-14 Vanderbilt University Vaccine for rsv and mpv
CN101990580A (zh) * 2008-04-04 2011-03-23 宾夕法尼亚州立大学托管会 屈曲病毒蛋白共有序列、编码该屈曲病毒蛋白共有序列的核酸分子和组合物及其使用方法
US20100040650A1 (en) * 2008-05-30 2010-02-18 Crowe Jr James E Virus-Like paramyxovirus particles and vaccines
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
US8680258B2 (en) 2008-12-01 2014-03-25 Alphavax, Inc. Use of microRNAs to control virus helper nucleic acids
AU2010234362B2 (en) 2009-04-08 2015-11-26 Alphavax, Inc. Alphavirus replicon particles expressing TRP2
WO2012001196A2 (es) 2010-06-28 2012-01-05 Proyecto De Biomedicina Cima, S.L. Vectores alfavirales y usos de los mismos para la expresión de genes heterólogos
SG11201407595UA (en) 2012-05-21 2014-12-30 Univerisity Of California Generation of human ips cells by a synthetic self- replicative rna
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
CA3062591A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
WO2019124441A1 (en) 2017-12-20 2019-06-27 Vlp Therapeutics, Llc Alphavirus replicon particle
NL2022538B1 (en) 2019-02-08 2020-08-19 Academisch Ziekenhuis Groningen Methods for providing purified viral particles of Semliki Forest Virus (SFV), preparations obtainable thereby, and uses thereof.
JP7457733B2 (ja) 2019-05-30 2024-03-28 グリットストーン バイオ インコーポレイテッド 改変アデノウイルス
WO2021138447A1 (en) 2019-12-31 2021-07-08 Elixirgen Therapeutics, Inc. Temperature-based transient delivery of nucleic acids and proteins to cells and tissues
EP4179073A1 (en) * 2020-07-10 2023-05-17 Boehringer Ingelheim International GmbH Process for producing a purified rhabdovirus from cell culture
WO2022032196A2 (en) 2020-08-06 2022-02-10 Gritstone Bio, Inc. Multiepitope vaccine cassettes
WO2023220693A1 (en) 2022-05-12 2023-11-16 SunVax mRNA Therapeutics Inc. Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator
WO2023243679A1 (ja) * 2022-06-17 2023-12-21 学校法人日本医科大学 高力価ウイルスベクターの製造方法
CN115948351B (zh) * 2022-12-01 2023-11-14 杭州养生堂生物医药有限公司 一种分离纯化cvb1的方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138854B1 (en) * 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US5173418A (en) 1985-05-10 1992-12-22 Benzon Pharma, A/S Production in Escherichia coli of extracellular Serratia spp. hydrolases
US5091309A (en) * 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5091205A (en) 1989-01-17 1992-02-25 Union Carbide Chemicals & Plastics Technology Corporation Hydrophilic lubricious coatings
US5185440A (en) * 1989-06-20 1993-02-09 North Carolina State University cDNA clone coding for Venezuelan equine encephalitis virus and attenuating mutations thereof
SE9003978D0 (sv) * 1990-12-13 1990-12-13 Henrik Garoff Dna expressionssystem baserade paa ett virus replikon
US6770283B1 (en) * 1990-12-13 2004-08-03 Bioption Ab DNA expression systems based on alphaviruses
AU6172194A (en) * 1993-02-08 1994-08-29 Paravax, Inc. Defective sindbis virus vectors that express (toxoplasma gondii) p30 antigens
US20020102273A1 (en) * 1995-08-08 2002-08-01 Robert B. Grieve Use of alphavirus expression vectors to produce parasite anitgens
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
SE9401091D0 (sv) 1994-03-31 1994-03-31 Bioption Ab Alphavirus cDNA vectors
SE9401709D0 (sv) * 1994-05-18 1994-05-18 Mathilda Sjoeberg Improved alphavirus vectors for expression of heterologous DNA
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5755770A (en) 1995-01-31 1998-05-26 Boston Scientific Corporatiion Endovascular aortic graft
US5703057A (en) * 1995-04-07 1997-12-30 Board Of Regents The University Of Texas System Expression library immunization
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US5639650A (en) 1995-05-23 1997-06-17 The University Of North Carolina At Chapel Hill cDNA clone for South African Arbovirus No. 86
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5853719A (en) * 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
AU3447097A (en) * 1996-07-01 1998-01-21 Rhone-Poulenc Rorer S.A. Method for producing recombinant adenovirus
US5827658A (en) * 1996-08-09 1998-10-27 The United States Of America As Reprsented By The Department Of Health And Human Services Isolation of amplified genes via cDNA subtractive hybridization
US5824046A (en) 1996-09-27 1998-10-20 Scimed Life Systems, Inc. Covered stent
US5726022A (en) * 1996-11-18 1998-03-10 Lifespan Biosciences, Inc. Subtractive hybridization and capture methods and kits for differential isolation of nucleic acids including disease-associated sequences
DE69737107T2 (de) * 1996-11-20 2007-07-12 Introgen Therapeutics Inc., Austin Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US5958738A (en) * 1997-03-24 1999-09-28 Roche Diagnostics Corporation Procedure for subtractive hybridization and difference analysis
US6261570B1 (en) * 1997-05-20 2001-07-17 The United States Of America As Represented By The Secretary Of The Army Live attenuated virus vaccines for western equine encephalitis virus, eastern equine encephalitis virus, and venezuelan equine encephalitis virus IE and IIIA variants
GB9716611D0 (en) * 1997-08-07 1997-10-08 Cantab Pharmaceuticals Res Ltd Virus preparations and methods
AUPO856097A0 (en) 1997-08-14 1997-09-04 Commonwealth Scientific And Industrial Research Organisation Vector
US6197502B1 (en) * 1997-11-17 2001-03-06 Cytos Biotechnology Ag Expression cloning processes for the discovery characterization, and isolation of genes encoding polypeptides with a predetermined property
GB9804632D0 (en) * 1998-03-05 1998-04-29 Cantab Pharma Res Virus preparations and methods
FI106618B (fi) 1998-03-30 2001-03-15 Sandvik Tamrock Oy Sovitelma painenestekäyttöisen iskulaitteen, kuten esimerkiksi rikotuslaitteen yhteydessä
DE69942006D1 (de) * 1998-04-08 2010-03-25 Univ North Carolina Krebsimpfstoff enthaltend alphavirusrepliconpartikeln
US6844188B1 (en) * 1998-04-08 2005-01-18 University Of North Carolina At Chapel Hill Methods and modified cells for the treatment of cancer
US6146874A (en) * 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
US6495143B2 (en) * 1998-07-10 2002-12-17 The United States Of America As Represented By The Secretary Of The Army Botulinum neurotoxin vaccine
EP1117430A1 (en) * 1998-10-05 2001-07-25 Genzyme Corporation Genes differentially expressed in cancer cells to design cancer vaccines
US6242259B1 (en) * 1998-12-31 2001-06-05 Chiron Corporation Compositions and methods for packing of alphavirus vectors
US6329201B1 (en) * 1998-12-31 2001-12-11 Chiron Corporation Compositions and methods for packaging of alphavirus vectors
JP4637368B2 (ja) 1999-04-14 2011-02-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アルファウイルスに基づくベクター系を利用する免疫応答を生成するための組成物および方法
ES2243274T3 (es) 1999-07-02 2005-12-01 Endotex Interventional Systems, Inc. Stent flexible y estirable en forma de hoja.
ES2312447T3 (es) * 2000-05-31 2009-03-01 Novartis Vaccines And Diagnostics, Inc. Procedimiento para la purificacion de particulas de replicon alfavirus.
US6783939B2 (en) * 2000-07-07 2004-08-31 Alphavax, Inc. Alphavirus vectors and virosomes with modified HIV genes for use in vaccines
US6982087B2 (en) 2000-09-07 2006-01-03 The University Of North Carolina At Chapel Hill Vectors derived from South African Arbovirus No. 86
EP2198882A3 (en) * 2001-01-12 2010-10-13 Novartis Vaccines and Diagnostics, Inc. Nucleic acid mucosal immunization
WO2002099035A2 (en) * 2001-05-31 2002-12-12 Chiron Corporation Chimeric alphavirus replicon particles
US7045335B2 (en) * 2001-09-06 2006-05-16 Alphavax, Inc. Alphavirus replicon vector systems
WO2004055161A2 (en) * 2002-12-12 2004-07-01 The Board Of Regents Of The University Of Texas System Large scale production of packaged alphavirus replicons
WO2004055167A2 (en) 2002-12-13 2004-07-01 Alphavax, Inc. Alphavirus particles and methods for preparation
EP1608762B1 (en) 2003-03-20 2014-01-08 Alphavax, Inc. Improved alphavirus replicons and helper constructs
AU2004257214B2 (en) * 2003-07-11 2010-04-22 Alphavax, Inc. Alphavirus-based cytomegalovirus vaccines

Also Published As

Publication number Publication date
AU2003297041A1 (en) 2004-07-09
ZA200505517B (en) 2006-03-29
ES2890023T3 (es) 2022-01-17
ES2630222T3 (es) 2017-08-18
WO2004055167A3 (en) 2005-01-13
EP1590451B1 (en) 2015-09-16
IL169076A (en) 2010-05-31
JP5079981B2 (ja) 2012-11-21
BRPI0317276B1 (pt) 2020-09-15
CA2807515A1 (en) 2004-07-01
WO2004055167A2 (en) 2004-07-01
EP1590451A2 (en) 2005-11-02
CA2807515C (en) 2014-02-04
EP2290054B1 (en) 2017-03-29
JP2012210224A (ja) 2012-11-01
CA2509979C (en) 2013-02-26
BR122019005271B1 (pt) 2020-10-13
JP2006509524A (ja) 2006-03-23
EP3246399B1 (en) 2021-07-07
US20040166573A1 (en) 2004-08-26
CA2509979A1 (en) 2004-07-01
AU2003297041B2 (en) 2009-02-26
BRPI0317276B8 (pt) 2021-05-25
JP5727420B2 (ja) 2015-06-03
EP2290054A1 (en) 2011-03-02
US7078218B2 (en) 2006-07-18
EP1590451A4 (en) 2007-05-02
BR0317276A (pt) 2005-11-08
DK2290054T3 (da) 2017-07-03
NZ540657A (en) 2006-09-29
EP3246399A1 (en) 2017-11-22
DK1590451T3 (da) 2015-12-14
HK1082524A1 (zh) 2006-06-09
ES2552687T3 (es) 2015-12-01

Similar Documents

Publication Publication Date Title
DK3246399T3 (da) Alfavirus-partikler og fremgangsmåder til fremstilling
DE60310339D1 (de) Querträger und Herstellungsverfahren
NO20032220D0 (no) Löfteverktöy II og fremgangsmåte for anvendelse av samme
NO20031776D0 (no) Null-boringskomplettering og produksjonssystem
DE60311063D1 (de) Ausziehleiter und zugehörige herstellungsverfahren
DE60319810D1 (de) Anschwemmfiltermedien und herstellungs- und verwendungsverfahren
DE60319787D1 (de) Montageverfahren und -vorrichtung
DE60324888D1 (de) und Herstellungsverfahren
DK1478648T3 (da) Phosphorholdige forbindelser og anvendelser deraf
NO20042376L (no) Jordrensesystemer og fremgangsmater
NO20040640L (no) Anordning og fremgangsmate
DK1608445T3 (da) Konfigurationer og fremgangsmåder til kulstofindfangning
NO20032112D0 (no) Grensesnitt for visuale og scene-graf
DK3722533T3 (da) Flisebelysningsfremgangsmåder og systemer
IS7594A (is) Laxófoxifen tafla og húðun hennar
DE60331729D1 (de) Audiocodierungsverfahren und audiocodierungseinrichtung
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
IS8489A (is) Umritunarstillar og aðferðir þeirra
DE60302019D1 (de) Stiftsteckerelement und Herstellungsverfahren davon
NO20053443L (no) Innretning og fremgangsmate for fremstilling av isolasjonselementer
DE60221576D1 (de) Lötlegierung und lötverbindung
DE60236994D1 (de) Halbleiterbauelement und dessen Herstellungsverfahren
DK1662867T3 (da) Insekticid-forbindelser og fremgangsmåder til valg deraf
DE60332140D1 (de) Halbleiterlaserbauelement und dessen herstellungsverfahren
ATE445542T1 (de) Flaschenkasten und herstellverfahren